While ccRCC tumors are considered resistant to chemotherapy, the recognition that TP is overexpressed in ccRCC tumors provided the rationale for the use of capecitabine, a 5-FU pro-drug activated by TP, in combination with selenium and biologically targeted molecules. This evidence concerns the gene TYMP and nonpapillary renal cell carcinoma.